Form PTO-1449 INFORMATION DISCLOSURE CIT. ON ON AN APPLICATION					cket Number (Optional) A-011.01(20777-1101)		Application Number 09/758,957				
(Use several sheets if necessary)					Applicant Hanson and Babich				8	SEF	
SEP 1 0 2001 B					Filing Date			p Art Unit	THE STATE OF THE S	<del></del>	
January 11, 2001 1614 5 5 11 1614 5 5 11 1614 5 5 11 1614											
EXAMINATE INITIAL	A DENAMENT NUMBER DA				NAME	CLA	CLASS		$\bowtie$ F	ILENG D APPROP	
MS	AA	US 4,634,792	01/06/8	37	Zanno et al.	560		169	8		<u>y</u>
MYS	AB	US 5,208,260	05/04/9	93	Cordi et al.	514		561	_		
•									<u> </u>		
										, <u></u>	
•	<u> </u>			i					<del> </del>		
•											
									ļ		
FOREIGN PATENT DOCUMENTS											
	D	OCUMENT NUMBER	DATE		COUNTRY	CLASS		SUBCLASS		Translation YES NO	
MS	AC	WO 99/61055	12/02/9	99	WIPO	,					X
MS	AD	WO 98/00398	01/08/9	98	ACT WIPO						
M	ΑE	EP 0 315 519 A2	05/10/8	39	European Patent Application						X
MS	AF	EP 0 263 502 A2	04/13/8	38	European Patent Application						X
ING	AG	EP 0 417 803 A1	03/20/9	91	European Patent Application						Х
/			ER DO		112			r, Title, Date, Pe			
W	ΑН	Mewshaw et al., "New Generation Dopaminergic Agents. 1. Discovery of a Novel Scaffold Which Embraces the D₂ Agonist Pharmacophore. Structure- Activity Relationships of a Series of 2-(Aminomethyl ) Chromans", J. Med. Chem. 40: 4235-4256, (1997).									
MS	ΑI	Jacoby et al.; "A Structural Rationale for the Design of Water Soluble Peptide-Derived Neurokinin-1 Antagonists", J. Recept. Signal Transduction Res. 17(6):855-873, (1997)									
B	ΑJ	International Search Report Completed on July 25, 2001, and mailed on August 08, 2001									
EXAMINER	DATE CONSIDERED 7/19/0										
	<u> </u>	112					14/	11/02			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.											

k